Strata Skin Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$SSKN
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 29, 2024
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company. ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
On October 29, 2024 the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted upon were:
(1) the election of five director nominees to the Company’s board of directors to serve until the next annual meeting of the Company’s stockholders or until their
successors are elected and qualify, subject to their prior death, resignation or removal;
(2) to ratify the selection by the Audit Committee of the Board of Directors of Marcum, LLP as our independent registered public accounting firm for the
fiscal year ending December 31, 2024; and
(3) to approve other business as may
properly come before the meeting.
The results of the voting were as follows:
(1) Each of the director nominees to the Company’s board of directors was elected:
|
Nominees
|
Votes For
|
Votes Withheld
|
Broker Non-Vote
|
|
Dr. Uri Geiger
|
2,308,422
|
141,987
|
1,039,279
|
|
Dr. Irit Yaniv
|
2,158,458
|
21,972
|
1,039,279
|
|
Christina Allgeier
|
2,308,422
|
141,987
|
1,039,279
|
|
Shmuel Rubinstein
|
2,173,350
|
7,080
|
1,039,279
|
|
Dr. Dolev Rafaeli
|
2,308,422
|
141,724
|
1,039,279
|
(2) to ratify the selection by the Audit Committee of the Board of Directors of Marcum, LLP as our independent registered public accounting firm for the
fiscal year ending December 31, 2024, was approved
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Vote
|
||||
|
3,166,313
|
53,201
|
195
|
0
|
(3) to approve other business as may properly come before the meeting
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Vote
|
||||
|
1,944,264
|
232,596
|
3,569
|
1,039,279
|
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: October 30, 2024
|
By:
|
/s/ Dolev Rafaeli
|
|
|
Dr. Dolev Rafaeli
|
|||
|
Chief Executive Officer
|
|||
-3-